Skip to main content

CORRECTION article

Front. Immunol., 05 January 2024
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1346845
This article is part of the Research Topic Comprehensive Profiling Cancer Immunity with Multimodal Approaches for Clinical Management View all 9 articles

Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study

This article is a correction to:

  1. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study

    1. Read original article
Wen-Jie Wu,,Wen-Jie Wu1,2,3Qian Liu,,Qian Liu1,2,3Pu-Gen An,,Pu-Gen An1,2,3Lin Wang,,Lin Wang1,2,3Jian-Yun Zhang,,Jian-Yun Zhang2,3,4Yan Chen,,Yan Chen2,3,4Tong ZhangTong Zhang5Jie Zhang,,*Jie Zhang1,2,3*
  • 1Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China
  • 2National Center of Stomatology & National Clinical Research Center for Oral Diseases, Beijing, China
  • 3Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China
  • 4Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China
  • 5Departmet of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

A Corrigendum
Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study

by Wu W-J, Liu Q, An P-G, Wang L, Zhang J-Y, Chen Y, Zhang T and Zhang J (2023) Front. Immunol. 14:1282629. doi: 10.3389/fimmu.2023.1282629

Text Correction

In the published article, there was an error. Some of the statements in the article about the results in Figure 2A were inappropriate.

A correction has been made to Results, Efficacy of neoadjuvant therapy, Line 3-9, Paragraph 2, Page 3. This sentence previously stated:

“A significant difference was observed in the median OS in the MPR (20 months) and non-MPR groups (16 months) respectively (p = 0.0138). In addition, the median DFS showed significant difference and in the MPR (18.5 months) and non-MPR groups (12 months), respectively, (p < .001) (Figure 2A).”

The corrected sentence appears below:

“A significant difference was observed in the OS between the MPR and non-MPR groups (p = 0.0138). In addition, the DFS showed a significant difference between the MPR and non-MPR groups (p < .001) (Figure 2A).”

In the published article, there was an error. Some of the statements in the article about the results in Figure 4B were inappropriate.

A correction has been made to Results, Survival, Line 4-9, Page 5. This sentence previously stated:

“Prognostic evaluation based on the PD-L1 CPS status revealed median OS durations of 22, 19, and 19 months for patients with PD-L1 CPS < 1, 1≤PD-L1 CPS <20, and PD-L1 CPS≥20, respectively (p = .3825). Median DFS durations for the three groups were consistently 16 months (p = .0244) (Figure 4B).”

The corrected sentence appears below:

“Prognostic evaluation based on the PD-L1 CPS status revealed that there was no significant difference in the OS among patients with PD-L1 CPS < 1, 1≤PD-L1 CPS <20, and PD-L1 CPS≥20 (p = .3825). But there was a significant difference in the DFS among the three groups (p = .0244) (Figure 4B).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: neoadjuvant, immunotherapy, chemotherapy, head and neck, squamous cell carcinoma

Citation: Wu W-J, Liu Q, An P-G, Wang L, Zhang J-Y, Chen Y, Zhang T and Zhang J (2024) Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study. Front. Immunol. 14:1346845. doi: 10.3389/fimmu.2023.1346845

Received: 30 November 2023; Accepted: 18 December 2023;
Published: 05 January 2024.

Edited and Reviewed by:

D. P. Kreil, University of Natural Resources and Life Sciences, Vienna, Austria

Copyright © 2024 Wu, Liu, An, Wang, Zhang, Chen, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jie Zhang, zhangjie123@bjmu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.